Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$181000.0.

  • Arcturus Therapeutics Holdings' Cash from Investing Activities fell 12625.0% to -$181000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$318000.0, marking a year-over-year increase of 7912.02%. This contributed to the annual value of -$648000.0 for FY2024, which is 7766.29% up from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its Cash from Investing Activities stood at -$181000.0 for Q3 2025, which was down 12625.0% from -$137000.0 recorded in Q1 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Cash from Investing Activities ranged from a high of $378000.0 in Q2 2022 and a low of -$3.8 million during Q4 2022
  • For the 5-year period, Arcturus Therapeutics Holdings' Cash from Investing Activities averaged around -$882294.1, with its median value being -$404000.0 (2021).
  • Data for Arcturus Therapeutics Holdings' Cash from Investing Activities shows a peak YoY increase of 19356.44% (in 2022) and a maximum YoY decrease of 168898.31% (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Cash from Investing Activities stood at -$1.1 million in 2021, then tumbled by 240.52% to -$3.8 million in 2022, then skyrocketed by 77.02% to -$875000.0 in 2023, then surged by 90.86% to -$80000.0 in 2024, then plummeted by 126.25% to -$181000.0 in 2025.
  • Its Cash from Investing Activities stands at -$181000.0 for Q3 2025, versus -$137000.0 for Q1 2025 and -$80000.0 for Q3 2024.